| Dr Peter Andrew Marcovici, MD | |
|
10180 Se Sunnyside Rd, Kaiser Sunnyside Medical Center, Clackamas, OR 97015-8970 | |
| (503) 571-8656 | |
| (503) 571-5869 |
| Full Name | Dr Peter Andrew Marcovici |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 18 Years |
| Location | 10180 Se Sunnyside Rd, Clackamas, Oregon |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356540314 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085P0229X | Radiology - Pediatric Radiology | MD168419 (Oregon) | Secondary |
| 2085R0202X | Radiology - Diagnostic Radiology | MD168419 (Oregon) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kaiser Sunnyside Medical Center | Clackamas, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kaiser Foundation Health Plan Of The Northwest | 5799688230 | 1482 |
| Kaiser Foundation Health Plan Of The Northwest | 5799688230 | 1482 |
News Archive
Oncotarget published "Appropriate body mass index cutoffs for type 2 diabetes in Xinjiang population: defining the influence of liver aminotransferase" which reported that these authors retrospective cohort study, T2DM was diagnosed when FBS ≥ 7.0 mmol/L, BMI of participants with baseline fasting < 7.0 mmol/L was divided by percentiles and by aminotransferanse .
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Children's Hospital Los Angeles was honored by The Healthcare Colloquium as the first west coast pediatric hospital to achieve designation as an Accredited Pediatric Heart Failure Institute.
CombinatoRx, Incorporated today announced that it has received a milestone payment from Fovea Pharmaceuticals, a division of Sanofi Aventis, relating to Fovea's initiation of Phase 2b clinical testing of PrednisporinTM (FOV1101) in subjects with persistent allergic conjunctivitis. Prednisporin™ is a CombinatoRx-derived combination drug candidate that was exclusively licensed to Fovea by CombinatoRx.
› Verified 3 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Northwest |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184786527 PECOS PAC ID: 5799688230 Enrollment ID: O20040130000799 |
News Archive
Oncotarget published "Appropriate body mass index cutoffs for type 2 diabetes in Xinjiang population: defining the influence of liver aminotransferase" which reported that these authors retrospective cohort study, T2DM was diagnosed when FBS ≥ 7.0 mmol/L, BMI of participants with baseline fasting < 7.0 mmol/L was divided by percentiles and by aminotransferanse .
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Children's Hospital Los Angeles was honored by The Healthcare Colloquium as the first west coast pediatric hospital to achieve designation as an Accredited Pediatric Heart Failure Institute.
CombinatoRx, Incorporated today announced that it has received a milestone payment from Fovea Pharmaceuticals, a division of Sanofi Aventis, relating to Fovea's initiation of Phase 2b clinical testing of PrednisporinTM (FOV1101) in subjects with persistent allergic conjunctivitis. Prednisporin™ is a CombinatoRx-derived combination drug candidate that was exclusively licensed to Fovea by CombinatoRx.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Peter Andrew Marcovici, MD 57 Lurline St, San Francisco, CA 94122-3549 Ph: (619) 964-9143 | Dr Peter Andrew Marcovici, MD 10180 Se Sunnyside Rd, Kaiser Sunnyside Medical Center, Clackamas, OR 97015-8970 Ph: (503) 571-8656 |
News Archive
Oncotarget published "Appropriate body mass index cutoffs for type 2 diabetes in Xinjiang population: defining the influence of liver aminotransferase" which reported that these authors retrospective cohort study, T2DM was diagnosed when FBS ≥ 7.0 mmol/L, BMI of participants with baseline fasting < 7.0 mmol/L was divided by percentiles and by aminotransferanse .
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
Children's Hospital Los Angeles was honored by The Healthcare Colloquium as the first west coast pediatric hospital to achieve designation as an Accredited Pediatric Heart Failure Institute.
CombinatoRx, Incorporated today announced that it has received a milestone payment from Fovea Pharmaceuticals, a division of Sanofi Aventis, relating to Fovea's initiation of Phase 2b clinical testing of PrednisporinTM (FOV1101) in subjects with persistent allergic conjunctivitis. Prednisporin™ is a CombinatoRx-derived combination drug candidate that was exclusively licensed to Fovea by CombinatoRx.
› Verified 3 days ago
Dr. Clay Anthony Elrod, D.O. Radiology Medicare: Accepting Medicare Assignments Practice Location: 10180 Se Sunnyside Rd, Clackamas, OR 97015 Phone: 503-652-2880 | |
Joshua Robert Hill, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 10180 Se Sunnyside Rd, Clackamas, OR 97015 Phone: 503-652-2880 | |
Garry Roger Dion, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 10180 Se Sunnyside Rd, Clackamas, OR 97015 Phone: 503-652-2880 | |
Jerry Everett King, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 10180 Se Sunnyside Rd, Clackamas, OR 97015 Phone: 503-652-2880 | |
Mark Robert Hurt, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 10180 Se Sunnyside Rd, Clackamas, OR 97015 Phone: 503-652-2880 | |
Dr. Susan Irene Wolf, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 10180 Se Sunnyside Rd, Kaiser Sunnyside Medical Office, Clackamas, OR 97015 Phone: 503-652-2880 | |
Dr. Brian James Markey, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 10180 Se Sunnyside Rd, Clackamas, OR 97015 Phone: 503-652-2880 |